Supreme Court Upholds FDA Regulation on Popular Abortion Drug Mifepristone from dap v Watch Video

⏲ Duration: 1:30
👁 View: 35K times
✓ Published: 14-Jun-2024

Description:
Supreme Court Upholds , FDA Regulation on Popular , Abortion Drug Mifepristone.<br/>On June 13, the Supreme Court ruled against a group of <br/>doctors who challenged the Food and Drug Administration's <br/>(FDA) regulations on the abortion pill mifepristone.<br/>CBS reports that the case once again highlighted <br/>abortion access following the conservative <br/>majority decision to overturn Roe v. Wade in 2022.<br/>The court ruled unanimously that the group of <br/>anti-abortion rights doctors and medical associations <br/>lacked the legal right to challenge the FDA. .<br/>However, the court also did not address <br/>whether the FDA's decision to relax the <br/>rules for mifepristone's use were lawful. .<br/>The latest ruling was authored <br/>by Justice Brett Kavanaugh. .<br/>Under Article III of the Constitution, <br/>a plaintiff's desire to make a drug <br/>less available for others does <br/>not establish standing to sue. , Justice Brett Kavanaugh writing for the court, via CBS.<br/>Nor do the plaintiffs' other <br/>standing theories suffice. <br/>Therefore, the plaintiffs lack <br/>standing to challenge FDA's actions, Justice Brett Kavanaugh writing for the court, via CBS.<br/>CBS reports that the ruling does not impact other <br/>challenges to the FDA's standing on mifepristone, <br/>while preserving access to the popular abortion medication.<br/>In 2016 and 2021, the FDA took steps to widen access <br/>to mifepristone, which has been taken by over <br/>5 million patients since first being approved in 2000.<br/>Those steps included allowing the drug to be taken up to 10 <br/>weeks into a pregnancy, reducing the number of in-person <br/>doctor visits and permitting it to be sold through the mail.